fMRI [functional magnetic resonance imaging] and Genotype Markers of Antidepressant [escitalopram] Side Effects and Response in Young Adults Compare to Older Adults

Trial Profile

fMRI [functional magnetic resonance imaging] and Genotype Markers of Antidepressant [escitalopram] Side Effects and Response in Young Adults Compare to Older Adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 26 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top